Discover
HOPA Now
HOPA Now
Author: Hematology/Oncology Pharmacy Association
Subscribed: 5Played: 2Subscribe
Share
© Hematology/Oncology Pharmacy Association
Description
Welcome to HOPA Now, a podcast from the Hematology/Oncology Pharmacy Association. Join hosts Benjamin Andrick, PharmD, BCOP and Matt Mueller as they interview guests in the Hem/Onc pharmacy world to provide insight into the topics that Hematology/Oncology pharmacists and cancer patients are talking about.
Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you.
Email us at [email protected]
Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you.
Email us at [email protected]
28 Episodes
Reverse
Precision medicine in oncology holds a lot of promise for personalized treatment - and requires a lot of collaboration! How are practices and institutions implementing it? What are some of the sticking points? What topics aren't being talked about enough? What should pharmacists be demanding out of various tests, trials and diagnoses? To identify and lead us through some of these important conversations, Ben and Matt are joined by HOPA members Mya Tran, PharmD, BCOP, a Precision Genomics Oncology Clinical Pharmacist at Indiana University Health's Simon Comprehensive Cancer Center in Indianapolis; and Noor Naffakh, PharmD, MS, BCOP, a Clinical Assistant Professor in the Department of Pharmacy Practice at the Retzky College of Pharmacy at the University of Illinois Chicago.Find out more about HOPA’s Precision Oncology Initiative here: https://www.hoparx.org/resources/precision-oncology-initiative/ You can read the paper Noor mentions about Discordance Recommendation Rate and Drug Cost Avoidance here: https://pubmed.ncbi.nlm.nih.gov/36265115/ Noor refers to a joint program between HOPA and ACCP for a certificate in Oncology Genomics – the credits for this live program have since expired, but we may provide a future opportunity like this. Find out more here: https://www.accp.com/education/oncgx26/ You can also learn about a past program similar to this that ACCP offered here: https://www.accp.com/education/pgx/ Find out more about Trial GPT here: https://www.ncbi.nlm.nih.gov/research/trialgpt/ Noor featured in one of the videos from our Time To Talk: Diversity in Clinical Trials campaign, discussing Biomarkers. It can be viewed here: https://www.youtube.com/watch?v=qQkSjG9WIYA Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at [email protected]
GLP-1s are one of the hottest hot-button topics in cancer care right now. Not only are these weight-loss drugs becoming more common among the public, but several studies seem to think they could actually help reduce the risk of certain cancer. What are the implications regarding insurance? What potential risks are involved with drug interactions? How do practitioners adjust the treatment plans for patients already using GLP-1s, or would benefit from taking them? To answer these questions and more, Matt and Ben are joined by HOPA member Jennifer MacDonald, PharmD, BCOP, Oncology Clinical Pharmacy Specialist at the Medical University of South Carolina in Charleston; and Mohammed Chammout, PharmD, BCMTMS a Clinical Access and Reimbursement Specialist based in Dearborn, Michigan, and founder of MKC Strategic Solutions, a consulting practice focused on specialty drug access, benefit verification, and PBM policy.The ASCO Abstract that Jennifer mentions can be viewed here: https://cdn.bfldr.com/KOIHB2Q3/as/w32hkswgp4jpg66kvw6f5rcs/AM26-Abstract_3143 Jennifer's articles for Pharmacy Times about GLP-1s relating to Endometrial Cancer can be read here: https://www.pharmacytimes.com/authors/jennifer-macdonald-pharmd-bcopMohammed's various articles about GLP-1s for Pharmacy Times can be read here: https://www.pharmacytimes.com/authors/mohammed-chammout-pharmd Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at [email protected]
Daraxonrasib is a drug that needs little introduction – it's the potential breakthrough in pancreatic cancer therapy that everyone’s been talking about for the past few weeks. It’s a total gamechanger in the fight against one of the deadliest, most aggressive cancers.What are the findings from the RASolute 302 trial? What does its recent FDA approval mean for pancreatic cancer therapy? And how does it impact your patients? HOPA members Courtney Cavalieri and Benjamin Andrick sat down to discuss everything you need to know.Check out Courtney's article on the drug in the latest issue of HOPA News.Find out more about Daraxonrasib in HOPA's Late-Breaking News article by Michael Arnold: https://www.hoparx.org/latest-news/late-breaking-hopa-news-rasolute-302-breakthrough-in-metastatic-pancreatic-adenocarcinoma/ Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at [email protected]
Optimism is an essential trait for oncology pharmacists, something that drives the practitioner's day-to-day and motivates the patient. But it can also transform how we approach the job, domestically and overseas.Diana Tamer, PharmD, BCOP is a clinical associate professor at the University of Missouri-Kansas City school of pharmacy. Originally from Lebanon, and passionate about pursuing a career in dance, her journey changed and led her to practice Oncology Pharmacy in the USA.Peter and Matt sat down with Diana for an inspiring conversation, learning about her experiences volunteering in Côte d'Ivoire through a HOPA initiative; how her faith guides her; and the differences in American and Lebanese oncology pharmacy.Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at [email protected]
Cancer care requires harmonious teamwork for the benefit of our patients. Every voice counts, and every opinion should be respected. But sometimes, differences between generations risk impacting that delicate balance. How does a multi-generational team play to each other's strengths, work on improving each other's weaknesses, and reach compromises that benefit everyone?Matt and Peter connected with Millennial Edna Cheung, PGY2 Hematology/Oncology Residency Program Director at Stanford Health Care and Gen-Z Logan Dugas, PGY-2 Resident Oncology Pharmacist at Moffitt Cancer Center. Logan and Edna had a wide-ranging discussion on how they tackle burnout, and what they've learned from peers of all ages.Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at [email protected]








